Related Experiment Video
Updated: May 5, 2026
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Published on: November 2, 2014
Exploring the effects of paclitaxel-loaded zein nanoparticles on human ovarian carcinoma cells
Stefania Scicchitano1, Agnese Gagliardi2, Nicola Ambrosio2
1Laboratory of Biochemistry and Cellular Biology, Department of Experimental and Clinical Medicine, University of Catanzaro Magna Græcia, 88100, Catanzaro, Italy.
Abstract:
The development of innovative antitumor formulations that are able to increase the mortality of cancer cells while decreasing the efficacious pharmacological dosage is a fundamental goal of modern oncological research. In this study a paclitaxel (PTX)-nanomedicine was tested on two lines of human high-grade serous ovarian carcinoma (hHGS-OC). Zein, a vegetal protein, was employed to obtain nanoparticles containing the lipophilic compound (NanoPTX) characterized by a mean diameter of 160 nm, a narrow size distribution, a negative zeta potential and a prolonged release of the drug over time. NanoPTX was tested on HEY and COV362 cells demonstrating an increase of apoptosis, particularly on the papillary cystadenocarcinoma cells (55.2% p value 0.037 for NanoPTX vs 70.25%, p value 0.08 for PTX) with respect to the free form of the drug. The fluorescent nanosystems were characterized by a significant cell uptake after a few hours of incubation and they promoted a reduction in the intracellular reactive oxygen species. The results need to be validated on different hHGS-OC cells and the real efficacy of the proposed nanomedicine needs to be investigated using in vivo models of ovarian carcinoma.
Insights
This study developed paclitaxel (PTX) nanoparticles using zein protein for ovarian cancer treatment. The novel nanomedicine (NanoPTX) enhanced cancer cell death and reduced drug dosage, showing promise for improved oncology therapies.
Area of Science:
- Oncology
- Nanomedicine
- Biomaterials
Background:
- Developing effective antitumor formulations is crucial in cancer research.
- Reducing drug dosage while increasing cancer cell mortality is a primary goal.
- Paclitaxel (PTX) is a key chemotherapeutic agent requiring improved delivery systems.
Purpose of the Study:
- To create and evaluate a novel paclitaxel (PTX) nanomedicine for high-grade serous ovarian carcinoma (hHGS-OC).
- To investigate the efficacy of zein-based nanoparticles loaded with PTX (NanoPTX) in vitro.
- To assess the potential of NanoPTX to enhance apoptosis and reduce reactive oxygen species in ovarian cancer cells.
Main Methods:
- Zein protein was used to formulate paclitaxel-loaded nanoparticles (NanoPTX).
- NanoPTX characterized for size (160 nm), zeta potential (negative), and drug release kinetics.
- In vitro testing on HEY and COV362 human high-grade serous ovarian carcinoma (hHGS-OC) cell lines.
Main Results:
- NanoPTX demonstrated increased apoptosis in hHGS-OC cells compared to free PTX.
- Significant cellular uptake of fluorescent NanoPTX observed within hours.
- NanoPTX promoted a reduction in intracellular reactive oxygen species.
Conclusions:
- Zein-based paclitaxel nanoparticles (NanoPTX) show potential as an effective antitumor formulation for ovarian cancer.
- Further validation in diverse hHGS-OC cell lines and in vivo models is warranted.
- NanoPTX may offer a strategy for enhanced efficacy and reduced dosage in ovarian cancer therapy.
